<DOC>
	<DOCNO>NCT01777308</DOCNO>
	<brief_summary>The purpose study evaluate immunogenicity , reactogenicity safety booster dose GSK Biologicals ' MenACWY-TT vaccine administer 6 year post-primary vaccination either GSK Biologicals ' Hib-MenC-TT vaccine ( Menitorix™ ) Hiberix™ Meningitec™ , healthy subject age 12-18 month primary vaccination evaluate long-term antibody persistence 2 year MenACWY-TT booster vaccination . This extension study Hib-MenC-TT-016 study ( NCT number : NCT00326118 ) .</brief_summary>
	<brief_title>Immunogenicity , Reactogenicity Safety GlaxoSmithKline ( GSK ) Biologicals ' MenACWY-TT Vaccine Administered 6 Years Post-MenC Primary Vaccination Healthy Subjects Who Were 12-18 Months Primary Vaccination</brief_title>
	<detailed_description />
	<mesh_term>Meningococcal Infections</mesh_term>
	<mesh_term>Vaccines</mesh_term>
	<criteria>Subjects ' parent ( ) /Legally Acceptable Representative ( ) , opinion investigator , comply , requirement protocol . A male female , include , 84 95 month age time booster vaccination . Written inform consent obtain parent ( ) /LAR ( ) subject write informed assent obtain subject accordance local law regulation . Healthy subject establish medical history historydirected physical examination enter study . Having complete vaccination study [ HibMenCTT016 ( 106445 ) ] per protocol . Child care . Use investigational nonregistered product ( drug vaccine ) study vaccine within 30 day precede dose study vaccine , plan use study period . Chronic administration immunosuppressant immunemodifying drug within six month prior vaccine dose . For corticosteroid , mean prednisone ≥ 0.5 mg/kg/day , equivalent . Inhaled topical steroid allow . Administration vaccine foreseen study protocol within period start 30 day end 30 day study vaccine dose , exception license inactivated influenza vaccine administer time study accord local recommendation . Concurrently participate another clinical study , time study period , subject expose investigational noninvestigational vaccine/product . Previous vaccination meningococcal vaccine except meningococcal vaccination receive HibMenCTT016 study . History meningococcal disease . Any confirm suspected immunosuppressive immunodeficient condition ( congenital secondary ) , include Human Immunodeficiency Virus ( HIV ) infection , base medical history physical examination ( laboratory testing require ) . Family history congenital hereditary immunodeficiency . History reaction hypersensitivity likely exacerbate component vaccine , history serious allergic reaction ( anaphylaxis ) follow administration vaccine ( ) . Major congenital defect serious chronic illness . History neurological disorder seizure , include GBS . History simple , single febrile seizure permit . Acute disease and/or fever time enrollment . Fever define temperature ≥ 37.5°C oral , axillary tympanic route , ≥ 38.0°C rectal route . The preferred route record temperature study oral . Subjects minor illness ( mild diarrhoea , mild upper respiratory infection ) without fever may enrol discretion investigator . Administration immunoglobulins and/or blood product within 3 month precede study vaccination plan administration booster vaccination phase study ( i.e . Visit 1 Visit 2 ) within 3 month precede blood sample Visit 3 . The following criterion check longterm persistence phase two year booster vaccination ( Visit 3 ) : In case exclusion criterion become applicable , subject enter longterm followup reason document . Previous administration meningococcal vaccine exception meningococcal vaccination give primary study booster vaccination particular study . History meningococcal disease .</criteria>
	<gender>All</gender>
	<minimum_age>84 Months</minimum_age>
	<maximum_age>95 Months</maximum_age>
	<verification_date>June 2016</verification_date>
	<keyword>Immunogenicity</keyword>
	<keyword>Booster</keyword>
	<keyword>Healthy</keyword>
	<keyword>Vaccine response</keyword>
	<keyword>Safety</keyword>
	<keyword>Neisseria meningiditis</keyword>
	<keyword>Antibody persistence</keyword>
	<keyword>Meningococcal conjugate vaccine</keyword>
</DOC>